China’s first GM rice gets US FDA approval
By Bai Tiantian,
Global Times
| 01. 22. 2018
A genetically modified (GM) rice product developed by a group of Chinese scientists has acquired the US Food and Drug Administration (FDA) approval, the first such Chinese product allowed to enter the US market.
However, neither China nor the US has approved mass cultivation of the rice amid low acceptance from the Chinese public for GM food.
Huahui No.1 rice, developed by the Huazhong Agricultural University, is genetically engineered to resist a wide range of insects, thus reducing the use of pesticides.
Lin Yongjun, a professor at Huazhong Agricultural University and one of the scientists that developed the rice, told the Global Times on Monday that Huahui No.1 could not be grown in China as "the country has not conducted regional trials nor provided guidelines to examine genetically engineered rice."
Lin said his team might consider growing Huahui No. 1 in Southeast Asian countries, "but our reach is limited and we hope the authorities can provide funding and legal support."
Lin's university received an email from the FDA on January 11 approving the rice.
The email, which was made public...
Related Articles
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...
By Alex Aylward, Daniel J. Fairbanks, Maria Kiladi, and Gregory Radick , Heredity | 04.20.2026
Genetics and eugenics co-evolved at the beginning of the twentieth century and remained associated through the 1940s and beyond. Early geneticists were far from unanimous in their views on eugenics; some avidly supported the movement, whereas others openly opposed it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...